Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Mylan Inc (NASDAQ: MYL) today and set a price target of $50. The company’s shares opened today at $37.84.
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 11.5% and a 47.6% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Mylan Inc has an analyst consensus of Moderate Buy, with a price target consensus of $48, a 26.8% upside from current levels. In a report issued on August 8, BMO Capital also reiterated a Buy rating on the stock with a $47 price target.
.
See today’s analyst top recommended stocks >>
Based on Mylan Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly net profit of $37.5 million. In comparison, last year the company had a net profit of $297 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe, Rest of World, and Corporate or Other.
